GENE ONLINE|News &
Opinion
Blog

2018-10-22| R&DTrials & Approvals

Roche’s breast cancer drug, Kadcyla succeeds phase III trial

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K Gopinath

Approved by the FDA in 2013, Kadcyla is used as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer who previously received Herceptin and a taxane.

On October 15th, Roche announced that the phase III KATHERINE study has met its primary endpoint, which was invasive disease-free survival (iDFS). This international, multi-centre, two-arm, randomised, open-label study showed that, in comparison to Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine) significantly reduced the risk of disease recurrence or death when used as an adjuvant treatment. The results of the study will be presented at the 2018 San Antonio Breast Cancer Symposium scheduled to be held in December.

Kadcyla is an antibody-drug conjugate (ADC) that combines the HER2-targeting property of the recombinant HER2 monoclonal antibody trastuzumab conjugated to the chemotherapy agent maytansinoid DM1 via a nonreducible thioether linkage. While the trastuzumab moiety binds to the tumor cells that overexpress HER2, the DM1 moiety binds to the tubulin of those cells and disrupt microtubule assembly/disassembly dynamics thereby proving detrimental to their growth and proliferation. Kadcyla is the third product of Roche following Herceptin and Perjeta (pertuzumab) that has helped to transform the treatment of HER2-positive breast cancer. At the moment, it is currently the only antibody drug conjugate approved as a single agent in 104 countries, including the US and EU.

Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development expressed her excitement. “We are highly encouraged by these positive results with adjuvant Kadcyla treatment in people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy. We look forward to discussions with regulatory authorities with the goal of bringing this new treatment option to patients as soon as possible.” she said.

References

  1. https://www.roche.com/media/releases/med-cor-2018-10-15.htm
  2. https://breastcancer-news.com/ado-trastuzumab-emtansine-kadcyla/

medtex最新-e1538653867506

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
ImmunoGen Wins FDA Accelerated Approval For Ovarian Cancer Drug
2022-11-16
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!